**Patient Notes: John Doe** 

**Patient ID: 123456** 

**Date of Birth:** 15/07/1955

Sex: Male

Admission Date: 10/10/2023 Discharge Date: 17/10/2023

**Primary Diagnosis:** Heart Failure with Reduced Ejection Fraction (HFrEF)

**Secondary Diagnoses:** 

- Ischaemic Heart Disease
- Hypertension
- Type 2 Diabetes Mellitus
- Chronic Kidney Disease (Stage 3)

## **Clinical History**

• **Presenting Complaint:** Shortness of breath (NYHA Class III), fatigue, and swelling in the lower limbs for the past 2 weeks.

### Past Medical History:

- Myocardial infarction (2018) with subsequent percutaneous coronary intervention (PCI).
- o Hypertension diagnosed in 2010, poorly controlled.
- o Type 2 Diabetes Mellitus diagnosed in 2012, on metformin.
- o Chronic Kidney Disease (eGFR 45 mL/min/1.73 m<sup>2</sup>).

#### • Medications on Admission:

- o Metoprolol tartrate 50 mg twice daily.
- o Ramipril 5 mg once daily.
- o Frusemide 40 mg once daily.
- Spironolactone 25 mg once daily.
- Metformin 500 mg twice daily.
- o Atorvastatin 40 mg once daily.

## **Examination Findings**

### Vitals:

Blood Pressure: 145/90 mmHg

o Heart Rate: 78 bpm

- Respiratory Rate: 22 breaths/min
- o Oxygen Saturation: 94% on room air

#### • Cardiovascular Exam:

- o Elevated jugular venous pressure (JVP).
- o S3 gallop heard on auscultation.
- o Bilateral pitting edema up to the knees.

## • Respiratory Exam:

o Bibasilar crackles on lung auscultation.

### **Investigations**

## Echocardiogram (10/10/2023):

- o Left Ventricular Ejection Fraction (LVEF): 32% (severely reduced).
- Mild mitral regurgitation.

#### Blood Tests:

- o Serum Potassium: 4.8 mmol/L (normal range: 3.5–5.0 mmol/L).
- o Serum Sodium: 135 mmol/L (normal range: 135–145 mmol/L).
- eGFR: 45 mL/min/1.73 m<sup>2</sup> (Stage 3 CKD).
- o HbA1c: 7.5% (suboptimal control).

## • Electrocardiogram (ECG):

o Sinus rhythm with left bundle branch block (LBBB).

## **Management During Admission**

## Medications Initiated/Adjusted:

- Metoprolol tartrate switched to carvedilol 12.5 mg twice daily (beta-blocker with mortality benefit in HFrEF).
- o Ramipril increased to **10 mg once daily** (ACE inhibitor).
- o Frusemide increased to **80 mg once daily** (loop diuretic).
- Spironolactone continued at 25 mg once daily (aldosterone antagonist).
- o Ivabradine **5 mg twice daily** added (heart rate control).

## Device Therapy:

Referral to cardiology for consideration of cardiac resynchronization therapy
(CRT) due to LBBB and LVEF <35%.</li>

## • Lifestyle Advice:

- Sodium restriction (<2 g/day).</li>
- Fluid restriction (<1.5 L/day).</li>
- Weight monitoring daily.

## Discharge Plan

## • Medications on Discharge:

- o Carvedilol 12.5 mg twice daily.
- o Ramipril 10 mg once daily.
- o Frusemide 80 mg once daily.
- Spironolactone 25 mg once daily.
- o Ivabradine 5 mg twice daily.
- o Metformin 500 mg twice daily.
- o Atorvastatin 40 mg once daily.

# Follow-Up:

- o Cardiology outpatient clinic in 4 weeks for CRT evaluation.
- o GP review in 1 week for blood pressure and renal function monitoring.